Accelerating Medicines Partnership for Parkinson's Disease (AMP-PD)

Introduction

<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | Accelerating Medicines Partnership for Parkinson's Disease (AMP-PD)
|-
| Established | 2019
|-
| Type | Public-Private Partnership
|-
| Lead Agencies | NIH (NINDS, NIA), FDA
|-
| Pharma Partners | 12+ pharmaceutical companies
|-
| Focus | Biomarker discovery and target validation
|}
</div>

Introduction

<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | Accelerating Medicines Partnership for Parkinson's Disease (AMP-PD)
|-
| Established | 2019
|-
| Type | Public-Private Partnership
|-
| Lead Agencies | NIH (NINDS, NIA), FDA
|-
| Pharma Partners | 12+ pharmaceutical companies
|-
| Focus | Biomarker discovery and target validation
|}
</div>

The Accelerating Medicines Partnership for Parkinson's Disease (AMP-PD) is a landmark public-private partnership designed to accelerate the development of new therapies for Parkinson's disease. By bringing together the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and multiple pharmaceutical companies, AMP-PD aims to identify and validate biomarkers, understand disease mechanisms, and enable more efficient clinical trials.

Background and Rationale

The Challenge of PD Drug Development

Parkinson's disease drug development faces significant challenges:

• Slow trial recruitment: Limited patient pools
• Heterogeneous disease: Multiple underlying mechanisms
• Biomarker gaps: No validated progression markers
• High failure rates: 95%+ of clinical trials fail

AMP-PD Solution

AMP-PD addresses these challenges through:

• Pre-competitive data sharing among pharma companies
• Integration of academic research expertise
• FDA regulatory science integration
• Open-access data and analytical resources

Partnership Structure

NIH Leadership

| Institute | Role |
|-----------|------|
| NINDS | Primary scientific lead |
| NIA | Aging and biomarker expertise |
| NCATS | Translational science support |
| NHLBI | Cardiovascular comorbidity expertise |

Pharmaceutical Partners

AMP-PD includes major pharmaceutical companies:

| Company | Contributions |
|---------|---------------|
| Biogen | Clinical trial data, expertise |
| Bristol Myers Squibb | Research collaboration |
| Eli Lilly | Compound libraries |
| Merck | Biomarker assays |
| Pfizer | Clinical data |
| Roche | Diagnostics development |
| Takeda | Research collaboration |
| Verily | Data analytics |

Governance

• Steering Committee: Strategic direction
• Working Groups: Scientific implementation
• External Advisory Board: Independent review

Research Programs

1. Biomarker Discovery

AMP-PD focuses on identifying:

| Biomarker Type | Clinical Application |
|----------------|---------------------|
| Diagnostic | Early PD detection |
| Progression | Disease staging |
| Prognostic | Outcome prediction |
| Pharmacodynamic | Drug target engagement |

Key Biomarker Platforms

• Proteomics: CSF and blood protein panels
• Genomics: Genetic risk scores
• Imaging: MRI, PET biomarkers
• Digital: Wearable device metrics

2. Target Validation

The partnership validates therapeutic targets:

| Target | Approach | Status |
|--------|---------|--------|
| [Alpha-synuclein](/proteins/alpha-synuclein) | Seeding assays | Validated |
| [LRRK2](/entities/lrrk2) | Kinase activity | In validation |
| [GBA1](/entities/gba) | Enzyme activity | In validation |
| [Tau](/proteins/tau) | Phospho-species | Exploratory |

3. Clinical Data Integration

AMP-PD aggregates clinical data from:

• Parkinson's Progression Markers Initiative (PPMI)
• Clinical trials (past and ongoing)
• Electronic health records
• Patient-reported outcomes

Data Resources

AMP-PD Data Platform

The program provides open-access data:

| Data Type | Samples | Access |
|-----------|---------|--------|
| Clinical data | 10,000+ | Open |
| Genomic data | 8,000+ | Open |
| Proteomics | 5,000+ | Open |
| Imaging | 3,000+ | Open |

Data Sharing Model

Industry Data → Harmonization → AMP-PD Platform →
Academic Analysis → Public Release → Published Findings

This pre-competitive model enables:

• Combined analysis without competition
• Faster biomarker validation
• Reduced duplicative efforts

Key Scientific Contributions

Alpha-Synuclein Research

AMP-PD has advanced alpha-synuclein biomarkers:

| Biomarker | Technology | Clinical Use |
|-----------|------------|--------------|
| α-synuclein RT-QuIC | Seed amplification | Diagnostic |
| CSF total α-syn | ELISA | Monitoring |
| CSF phosphorylated | ELISA | Target engagement |
| PET ligands | Imaging | Protein burden |

Genetic Stratification

The program integrates genetics with clinical data:

• GBA-PD: Increased risk, faster progression
• LRRK2-PD: Typical PD phenotype
• SNCA-PD: Rapid progression, dementia
• Polygenic risk: Overall risk stratification

Progression Markers

Longitudinal data enables progression marker discovery:

| Marker | Change with Progression | Utility |
|--------|------------------------|---------|
| Motor scores | Worsening | Clinical trials |
| Cognitive tests | Decline | Prognosis |
| Imaging markers | Atrophy | Monitoring |
| CSF biomarkers | Dynamic | Target engagement |

Impact on Drug Development

Specific Research Initiatives

Alpha-Synuclein Seed Amplification Assays

AMP-PD has been instrumental in developing and validating alpha-synuclein seed amplification assays (SAAs), including RT-QuIC (Real-Time Quaking-Induced Conversion) and PMCA (Protein Misfolding Cyclic Amplification)[@chen2023]. These assays detect misfolded alpha-synuclein in cerebrospinal fluid with high sensitivity (≈95%) and specificity (≈90%) for Parkinson's disease.

Key findings from AMP-PD studies:

• Diagnostic accuracy: SAAs can distinguish PD from healthy controls and other neurodegenerative disorders with high accuracy
• Prodromal detection: Positive signals detected in individuals with REM sleep behavior disorder (RBD), a PD prodrome, enabling early intervention
• Disease staging: Seeding activity correlates with disease duration and severity
• Trial enrichment: Biomarker-positive patients enable more efficient clinical trials

LRRK2 Kinase Activity Biomarkers

AMP-PD has established robust assays for measuring LRRK2 kinase activity in biological samples[@khr2023]:

| Assay | Sample Type | Application |
|-------|-------------|-------------|
| pSer935 LRRK2 | Blood (PBMCs) | Target engagement |
| pThr73 Rab10 | Blood | Kinase activity |
| pThr73 Rab10 | CSF | CNS penetration |
| LRRK2 auto-phosphorylation | Cell lines | Compound screening |

These biomarkers have been critical for:

• Demonstrating CNS penetration of LRRK2 inhibitors in clinical trials
• Establishing pharmacodynamic endpoints for dose selection
• Enabling patient enrichment strategies for LRRK2-targeted trials
• Supporting regulatory submissions for biomarker qualification

GBA Biomarker Program

The AMP-PD GBA research program has characterized the largest cohort of glucocerebrosidase (GBA) variant carriers with Parkinson's disease[@chare2023]:

• Genetic characterization: Over 2,000 GBA carriers across the AMP-PD cohort
• Phenotype analysis: Earlier onset, faster progression, higher cognitive decline risk
• Biomarker correlation: CSF glucosylsphingosine (Lyso-Gb1) as a pharmacodynamic marker
• Therapeutic development: GBA enzyme activity modulators advancing to clinical trials

• GBA variants account for 5-10% of all PD cases
• Carriers of severe GBA mutations progress 2-3x faster than non-carriers
• GBA enzyme activity in blood correlates with disease severity
• Lyso-Gb1 is a sensitive biomarker for GBA-targeted therapies

Tau and Neurodegeneration Markers

While primarily focused on alpha-synuclein, AMP-PD has also advanced tau biomarkers:

• CSF total tau and phospho-tau: Correlate with cognitive impairment in PD
• PET tau ligands: Emerging imaging biomarkers for tau pathology
• Neurofilament light chain (NfL): Validated as progression marker
• Alpha-synuclein-tau interactions: Investigated through multi-omics approaches

Clinical Cohorts and Studies

PPMI Integration

The Parkinson's Progression Markers Initiative (PPMI) is a cornerstone of AMP-PD[@ppmini2023]:

| PPMI Cohort | Participants | Key Features |
|-------------|---------------|--------------|
| De novo PD | 500+ | Untreated, recent diagnosis |
| Prodromal | 200+ | RBD, hyposmia, genetic risk |
| Healthy controls | 200+ | Age-matched |
| Genetic cohorts | 300+ | LRRK2, GBA, SNCA, PARKIN |
| SWEDD | 100+ | Important for diagnosis |

PPMI has generated:

• 10+ year longitudinal data on progression
• Biospecimen repository (CSF, blood, DNA)
• Imaging dataset (MRI, DAT scans)
• Digital biomarker data (smartphones, wearables)

Clinical Trial Data Integration

AMP-PD has integrated data from:

| Trial Program | Companies | Data Types |
|---------------|-----------|------------|
| LRRK2 inhibitor trials | Biogen, Denali, Roche | Clinical, biomarker |
| GBA trials | Sanofi, Pfizer | Clinical, genetic |
| Alpha-synuclein trials | Roche, Biogen, Novartis | Clinical, CSF biomarkers |
| Symptomatic trials | Multiple | Clinical, imaging |

This integration enables:

• Cross-trial comparisons and meta-analyses
• Identification of common progression markers
• Optimization of trial designs based on historical data
• Target validation through biomarker correlations

Data Science and Analytics

AMP-PD Knowledge Portal

The AMP-PD Knowledge Portal (ampdmarkers.org) provides:

• Cohort Browser: Interactive exploration of participant data
• Data Download: Tiered access (open, registered, controlled)
• Analysis Pipelines: Jupyter notebooks, R scripts
• Visualization Tools: Customizable plots and dashboards
• Documentation: Data dictionaries, methodology guides

Analytical Approaches

AMP-PD researchers have pioneered:

| Approach | Application | Key Outputs |
|----------|-------------|-------------|
| Multi-omics integration | Systems biology | Novel pathway discovery |
| Machine learning | Risk prediction | Polygenic risk scores |
| Survival analysis | Progression modeling | Prognostic biomarkers |
| Network analysis | Target identification | Module discovery |

Reproducibility Initiative

AMP-PD has implemented rigorous reproducibility standards:

• All analyses documented in notebook format
• Code shared via GitHub repositories
• Results validated in independent cohorts
• Pre-registration of hypothesis-testing studies

Therapeutic Development Impact

Target Validation Pipeline

AMP-PD has contributed to validation of multiple PD therapeutic targets:

| Target | Evidence Level | AMP-PD Contribution |
|--------|----------------|---------------------|
| Alpha-synuclein | Clinical (Phase 3) | Diagnostic biomarkers, patient selection |
| LRRK2 | Clinical (Phase 2) | Pharmacodynamic biomarkers, genetic stratification |
| GBA | Clinical (Phase 1/2) | Target engagement markers, patient enrichment |
| Tau | Preclinical/Phase 1 | Biomarker development |

Clinical Trial Design Improvements

AMP-PD data has influenced trial design:

• Enrichment strategies: Biomarker-positive selection
• Endpoint optimization: Validated progression markers
• Sample size reduction: Precision medicine approaches
• Digital endpoints: Use of wearable device data
• Regulatory interactions: FDA biomarker qualification support

Drug Repurposing

AMP-PD resources support drug repurposing:

• Existing compound libraries screened against AMP-PD data
• Known safety profiles accelerate development timelines
• Biomarker assays enable rapid readouts
• Clinical trial infrastructure supports rapid testing

Clinical Trial Optimization

AMP-PD resources enable better trials:

| Application | Example |
|-------------|---------|
| Patient selection | Genetic stratification |
| Enrichment | Biomarker-positive subjects |
| Outcome measures | Validated endpoints |
| Sample size | Precision medicine |

Repurposing Opportunities

Data resources support drug repurposing:

• Clinical trial data: Existing compound profiles
• Biomarker assays: Readily available
• Safety data: Known human safety
• Regulatory pathways: Established

Case Study: GLP-1 Agonists

AMP-PD contributed to repurposing efforts:

• Biomarker characterization for exenatide
• Patient stratification for trials
• Outcome measure standardization

Collaborative Projects

With GP2

AMP-PD works closely with the [Global Parkinson's Genetics Program](/institutions/gp2):

• Shared data resources
• Coordinated analyses
• Joint publications

With Industry

Pharma partners contribute:

• Historical trial data
• Assay development expertise
• Drug development experience

With Academic Centers

Academic researchers access:

• Open data resources
• Analysis pipelines
• Publication opportunities

Notable Outputs

Publications

| Year | Key Publication | Impact |
|------|-----------------|--------|
| 2020 | AMP-PD Whitepaper | Program foundation |
| 2021 | Biomarker Landscape | Comprehensive review |
| 2022 | Genetic Stratification | Precision medicine |
| 2023 | Progression Markers | Clinical utility |

Tools and Resources

| Resource | Purpose |
|----------|---------|
| AMP-PD Knowledge Portal | Data access |
| Analysis notebooks | Reproducible research |
| Biomarker assays | Standardized measurement |
| Data dictionaries | Harmonization |

Future Directions

Phase 2 Expansion (2024-2028)

Precision Medicine Implementation

AMP-PD aims to enable:

• Genotype-stratified clinical trials
• Biomarker-driven patient selection
• Personalized treatment approaches
• Preventive interventions for at-risk individuals

See Also

• [Global Parkinson's Genetics Program](/institutions/gp2)](/institutions)
• [International Parkinson's Disease Genomics Consortium](/institutions/ipdgc)](/institutions)
• [Parkinson's Disease Drug Repurposing Consortia](/institutions/parkinsons-disease-repurposing-consortia)](/institutions)
• [Parkinson's Progression Markers Initiative](/institutions/ppmi)](/institutions)
• [Michael J. Fox Foundation](/institutions/michael-j-fox-foundation)](/institutions)
• [Parkinson's Disease](/diseases/parkinsons-disease)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Accelerating Medicines Partnership for Parkinson's Disease (AMP-PD) discovered through SciDEX knowledge graph analysis: